Outlook Therapeutics, Inc. (OTLK)

NASDAQ: OTLK · Real-Time Price · USD
1.440
+0.050 (3.60%)
At close: Dec 20, 2024, 4:00 PM
1.410
-0.030 (-2.08%)
After-hours: Dec 20, 2024, 5:00 PM EST
3.60%
Market Cap 34.06M
Revenue (ttm) n/a
Net Income (ttm) -94.05M
Shares Out 23.66M
EPS (ttm) -5.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 706,023
Open 1.370
Previous Close 1.390
Day's Range 1.336 - 1.470
52-Week Range 0.870 - 12.850
Beta 0.51
Analysts Strong Buy
Price Target 40.57 (+2,717.36%)
Earnings Date Feb 12, 2025

About OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The compa... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 13, 2016
Employees 24
Stock Exchange NASDAQ
Ticker Symbol OTLK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for OTLK stock is "Strong Buy." The 12-month stock price forecast is $40.57, which is an increase of 2,717.36% from the latest price.

Price Target
$40.57
(2,717.36% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Outlook Therapeutics® Streamlines Operations

ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea...

7 days ago - GlobeNewsWire

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of w...

17 days ago - GlobeNewsWire

Outlook Therapeutics® Announces Executive Leadership Transition

ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea...

17 days ago - GlobeNewsWire

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Outlook Therapeutics Inc. OTLK revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients.

23 days ago - Benzinga

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea...

24 days ago - GlobeNewsWire

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET

6 weeks ago - GlobeNewsWire

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET Live video webcast with Russell Trenary, President and CEO of Outlook Thera...

3 months ago - GlobeNewsWire

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Webcast replay of fireside chat now available

3 months ago - GlobeNewsWire

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom e...

3 months ago - GlobeNewsWire

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ISELIN, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom e...

3 months ago - GlobeNewsWire

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

Outlook Therapeutics faces liquidity issues and delays in FDA approval for its Wet AMD therapy, leading to a downgrade from Strong Buy to Buy. The potential blockbuster market for LYTENAVA in treating...

Other symbols: AMD
4 months ago - Seeking Alpha

Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript

Outlook Therapeutics, Inc. Q3 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Jenene Thomas - JTC Team, LLC, Investor Relations Russell Trenary - President and Chief Exec...

4 months ago - Seeking Alpha

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

ISELIN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized u...

4 months ago - GlobeNewsWire

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-v...

4 months ago - GlobeNewsWire

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized u...

4 months ago - GlobeNewsWire

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

Company to participate in a fireside chat on Monday, August 5 th at 8:00 AM ET

5 months ago - GlobeNewsWire

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

ISELIN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-v...

5 months ago - GlobeNewsWire

Outlook Therapeutics: Worth A Good Strong Look After CRL

Outlook Therapeutics received a Complete Response Letter from the FDA in August 2023, causing a 74% drop in share price. Following a Type A meeting with the FDA in November 2023, Outlook agreed to con...

6 months ago - Seeking Alpha

Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market

Outlook Therapeutics is resubmitting a BLA for ONS-5010 by 2024, with top-line data expected in Q4, 2024. ONS-5010 received European Commission Marketing Authorization for treating wet AMD in May 2024...

6 months ago - Seeking Alpha

Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series

Live webcast on Thursday, June 13th at 4:00 PM ET FRENCHTOWN, NJ / ACCESSWIRE / June 12, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announc...

6 months ago - Accesswire

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizum...

6 months ago - GlobeNewsWire

Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Watch the "What This Means" video here Outlook CEO, Russ Trenary underscores that LYTENAVA™ (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commissio...

7 months ago - Accesswire

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

ISELIN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizuma...

7 months ago - GlobeNewsWire

Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Q2 2024 Earnings Conference Call May 16, 2024 8:30 AM ET Company Participants Jenene Thomas - IR, JTC Team, LLC Russell Trenary - President & CEO Lawrence Ken...

7 months ago - Seeking Alpha

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

ISELIN, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalm...

7 months ago - GlobeNewsWire